# US 10,945,986 B2 · Treatment for ischemic stroke

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,945,986 B2
- Document ID: US10945986B2
- Status: Granted
- Kind: B2
- Application number: 16/357,013
- Filed: 2019-03-18
- Published: 2019-07-11
- Granted: 2021-03-16
- Earliest claimed: 2012-03-29
- Assignees: CHS Pharma, Inc.
- Applicants: CHS Pharma, Inc.
- Inventors: Jang-Yen Wu; Howard Malcolm Prentice
- Web page: https://patentgrep.com/patent/US10945986B2

## CPC

- A61K 31/27: of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 38/193: {Colony stimulating factors [CSF]}
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Granulocyte colony-stimulating factor (G-CSF; a stem cell enhancer and facilitator), DETC-MeSO (a glutamate receptor partial antagonist and anti-excitotoxicity agent), and sulindac (a potent anti-oxidant and anti-inflammatory agent) each can protect brain tissue exposed to a cerebral ischemia/reperfusion injury, and minimize the size of infarcts that develop as a result of the injury. When administered in combination, these agents are effective at protecting brain tissue and minimizing the size of an infarct resulting from the injury at much lower concentrations compared to using a single agent.

## Claims

### Claim 1

A method of treating reperfusion injury in the brain of a mammalian subject, the method comprising the step of administering to the subject a N-diethylthiocarbamate sulfoxide (DETC-MeSO) agent, wherein the reperfusion injury is caused by a stroke.

### Claim 2 (depends on 1)

The method of claim 1, wherein the DETC-MeSO agent is administered to the subject within 24 hours of the onset of symptoms of the stroke.

### Claim 3 (depends on 1)

The method of claim 1, wherein the DETC-MeSO agent is repeatedly administered to the subject at least once per day for at least 3 days.

### Claim 4 (depends on 1)

The method of claim 1, wherein the DETC-MeSO agent is repeatedly administered to the subject at least once per day for at least 7 days.

### Claim 5 (depends on 1)

The method of claim 1, wherein the subject has been administered tissue plasminogen activator to treat the stroke.

### Claim 6 (depends on 1)

The method of claim 1, further comprising administering to the subject a sulindac agent.

### Claim 7 (depends on 1)

The method of claim 1, further comprising administering to the subject a granulocyte colony-stimulating factor (G-CSF) agent and a sulindac agent.